Home>Topics>>Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?
Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?
Long Investing Ideas from Seeking Alpha
Wed, 6 Feb 2013
By Prohost Biotech : We lived a long time with Elan ( ELN ) . We always appreciated its science and scientists, and, at times, we hated its former management, or whoever caused it to turn from ascending towards becoming a citadel of sciences, especially neurosciences, into an almost bankrupt firm ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.